Skip to main content

Oral IL-23 Inhibitor Effective in Psoriasis

The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). 

This phase 2 dose-finding trial randomized 255 PSO patients, with moderate-to-severe plaque psoriasis, to receive either placebo or study drug (25 mg qd; 25 mg bid; 50 mg qd; 100 mg qd, or 100 mg bid for 16 weeks. The primary end point was achieving at least 75% in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response) at week 16.RESULTS

Patients had active PSO with a mean PASI score at baseline was 19.1. The disease duration was 18.2 years, and 78% of patients previously received systemic treatments. At week 16 PASI 75 response for placebo was 9%, but was significantly higher with JNJ-77242113:

  • 25 mg qd: 37%
  • 25 mg bid: 51%
  • 50 mg qd: 58%
  • 100 mg qd: 65%
  • 100 mg bid: 79%

The most common adverse events included COVID19 (12% PBO; 11% JNJ-77242113 dose groups) and nasopharyngitis (PBO 5% and JNJ 7%,). There was no dose-related increase in adverse events across the JNJ-77242113 dose groups.

An orally administered, peptide against IL-23 was shown to be effect in patients with moderate-to-severe plaque psoriasis, in this phase II trial.


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject